ClinicalTrials.gg
Drug

SB939 compound clinical trials

Also written SB939 and Pracinostat.

studies test it
15
open now
0
in phase 3
1
first study started
2007

How each study uses SB939 compound is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

HDAC inhibitor SB939
2

Development codes

SB939
9

Other names

Pracinostat
8

Studies by the year they started

15 studies that test it; most in 2010 (4)

Studies that test SB939 compound, by start year
YearStudies
20072
20104
20133
20141
20151
20172
20181
20191

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
5
Phase 2
8
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 8 · Other 7

Helsinn Healthcare SA (7) · NCIC Clinical Trials Group (4) · M.D. Anderson Cancer Center (2) · Medical College of Wisconsin (1) · S*BIO (1)

Often tested with

Tested in the same studies.

Gemtuzumab (1) · Azacitidine (1)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses SB939 compound is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 15

Given beside what is tested · 1 — SB939 compound is usual care or a partner of the new treatment